share_log

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

SEC announcement ·  Jun 12 04:20
Summary by Futu AI
Recursion Pharmaceuticals, Inc. Director Blake Borgeson is set to sell 11,447 Class A shares of the company on 06/11/2024, as per the latest filing. The shares, valued at approximately $96,762.82, were originally acquired as founders shares on 09/01/2016 as part of compensation from the issuer. This planned sale follows a series of transactions over the past three months, where a total of 85,896 Class A shares were sold by Borgeson, generating gross proceeds of $803,931.52. The upcoming sale reflects ongoing trading activity by the director, with the specific intent and plan for this sale having been adopted on 08/18/2023.
Recursion Pharmaceuticals, Inc. Director Blake Borgeson is set to sell 11,447 Class A shares of the company on 06/11/2024, as per the latest filing. The shares, valued at approximately $96,762.82, were originally acquired as founders shares on 09/01/2016 as part of compensation from the issuer. This planned sale follows a series of transactions over the past three months, where a total of 85,896 Class A shares were sold by Borgeson, generating gross proceeds of $803,931.52. The upcoming sale reflects ongoing trading activity by the director, with the specific intent and plan for this sale having been adopted on 08/18/2023.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.